Early Diagnosis and Treatment Are Critical in Achieving the Best Outcomes in Sarcoma
Breelyn Wilky, MD, discusses the importance of disease screening and early diagnosis in the treatment of patients with sarcoma.
Related Articles
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Combination ICI Plus cCRT Appears Feasible for Stage III NSCLC
Researchers found that, in patients with stage III NSCLC, treatment with cCRT and an ICI was safe, but treatment with cCRT and 2 ICIs led…
Urinary DNA Methylation Test for Bladder Cancer Diagnosis
This prospective multicenter study including individuals with hematuria evaluates the performance of a urinary DNA methylation test in identifying patients with high-grade or invasive bladder…
Venetoclax Elicits Immune Synapse Repair in Chronic Lymphocytic Leukemia
Matthew Cortese, MD, MPH, discusses an evaluation of immunologic changes with the treatment of venetoclax in patients with chronic lymphocytic leukemia.
ESMO Targeted Anticancer Therapies Asia Congress 2025: Abstracts
The abstract submission is now open!
FDA Approves Acalabrutinib Plus Bendamustine and Rituximab for Previously Untreated MCL
The FDA has approved acalabrutinib plus bendamustine and rituximab for adult patients with previously untreated MCL who are ineligible for autologous HSCT.
CAR-T Meeting 2025 | VJHemOnc
Jointly organized by the EHA and EBMT, the 7th European CAR T-cell Meeting is taking place on February 6-8, 2025, in Strasbourg, France, and online,…
Real-world safety of trastuzumab deruxtecan in Japanese patients with gastric cancer
Hisato Kawakami, MD, PhD, Tohoku University, Sendai, Japan, comments on the real-world incidence of interstitial lung disease (ILD) and severe adverse events associated with trastuzumab…
Prostate-specific antigen screening at low thresholds of men with pathogenic BRCA1/2 variants
Prostate Cancer and Prostatic Diseases – Prostate-specific antigen screening at low thresholds of men with pathogenic BRCA1/2 variants
Obe-Cel Produces Durable Remissions in Adult R/R B-ALL
Obe-cel generated durable remissions in patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated during the FELIX trial.